Pfizer Limited

BSE: 500680 NSE: PFIZER
Pfizer Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24231MH1950PLC008311 Incorporated 21 November 1950 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: PFIZER · BSE: 500680 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹2,519.65 Cr
▲ 10.45% YoY
EBITDA · FY 2026
₹1,092.04 Cr
▲ 19.68% YoY
Net profit · FY 2026
₹722.43 Cr
▼ 5.88% YoY
Authorised capital
₹63 Cr
Registered with MCA
Paid-up capital
₹45.75 Cr
Issued & subscribed
Open charges
None
Secured borrowings
Company age
76 yrs
Est. 1950
Employees · EPFO
1,727
Latest available

About Pfizer Limited

Data last updated: 22 December 2025

Pfizer Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 21 November 1950, the company has been in operation for over 76 years.

Registered with ROC Mumbai under CIN L24231MH1950PLC008311. Listed on BSE: 500680 and NSE: PFIZER.

Capital: an authorised share capital of ₹63 Cr and a paid-up capital of ₹45.75 Cr. It is led by directors including Meena Ganesh and Pradip Panalal Shah.

Last AGM: 21 July 2025. Financial statements filed for year ended 31 March 2025. Office: The Capital 1802 / 1901 Plot No. C – 70 G Block Bandra Kurla Complex Bandra (East), Mumbai, Maharashtra, India – 400051.

As per the financials filed for FY 2025, the company reported a revenue of ₹2,453.6 Cr, a growth of 3% compared to the previous year.

The company has a workforce of approximately 1,727 employees as per the latest available data.

The company is associated with 1 brand - Pfizer.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website pfizerindia.com.

Company Details of Pfizer Limited
CIN L24231MH1950PLC008311
Registration Number 008311
Incorporation Date 21 November 1950
ROC Mumbai
Listing Status Listed (BSE: 500680, NSE: PFIZER)
Company Status Active
Date of Last AGM 21 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Meenakshi Nevatia Managing Director Pazhania Pillai Rengan Whole-Time Director Amit Agarwal Cfo
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    pfizerindia.com
  • Social Media
  • Registered Address
    The Capital 1802 / 1901 Plot No. C – 70 G Block Bandra Kurla Complex Bandra (East), Mumbai, Maharashtra, India – 400051
  • Industry
    Pharma, Drug Formulation & Development
Company report
Pfizer Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Pfizer Limited report

Financials, compliance, directors, charges, ownership and filings for Pfizer Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Pfizer Limited

Pfizer Limited operates one associated brand: Pfizer. These brands represent Pfizer Limited's diversified market presence and brand portfolio.

Brand Description Website
Pfizer
Pharmaceutical products for treating multiple diseases are provided. pfizer.com

Competitors & Alternatives of Pfizer Limited

Brands and companies operating in the same space as Pfizer Limited include Merck, Roivant Sciences, AbbVie and 7 more.

Competitor Description Location Founded
Merck Merck Pharmaceutical products are manufactured and marketed worldwide. Kenilworth, United Kingdom, United Kingdom 1891
Roivant Sciences Roivant Sciences Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. New York, United States, United States 2014
AbbVie AbbVie Biopharmaceutical research and drug development are conducted globally by AbbVie. Chicago, United States, United States 2012
Lilly Lilly Traditional pharmaceutical medicines are developed for multiple health fields. United States 1876
Gilead Gilead Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others Foster City, United States, United States 1987
Pharmaron Pharmaron Drug discovery and development services for small molecules are provided. Beijing, China, China 2003
United Therapeutics United Therapeutics Treatments for chronic and life-threatening diseases are developed and commercialized. Silver Spring, United States, United States 1998
Roche Roche Pharmaceuticals and diagnostics kits are developed for various diseases. Basel, Switzerland, Switzerland 1896
MorphoSys MorphoSys Therapeutic antibodies for cancer and other diseases are developed. Planegg, Germany, Germany 1992
Vertex Pharmaceuticals Vertex Pharmaceuticals Developer of drugs for the treatment of multiple disorders United States 1989

Business Activity of Pfizer Limited

Pfizer Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Pfizer Limited

Pfizer Limited is audited by B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Pfizer Limited

Pfizer Limited is currently managed by 8 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Meena Ganesh
Also directs: Vriksha Realtors Llp, Orkla India Limited, Pidilite Industries Limited and 5 more
Director 08 Mar 2019 7 Years 4 Months Current
Pradip Panalal Shah
Also directs: Basf India Limited, Bajaj Holdings & Investment Limited., Bajaj Auto Limited. and 5 more
Director 07 Dec 1999 26 Years 7 Months Current
Pazhania Pillai Rengan Whole-Time Director 06 Jan 2024 2 Years 6 Months Current
Amit Agarwal Cfo 26 Feb 2024 2 Years 4 Months Current
Prajeet Nair
Also directs: Wyeth Pharmaceuticals India Private Limited
Nodal Officer 03 Sep 2019 6 Years 10 Months Current
Sonia Singh
Also directs: Basf India Limited, Kansai Nerolac Paints Limited, Bharat Forge Ltd and 3 more
Director 29 Jul 2024 1 Years 11 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Pfizer Limited FY 2026 filings available

Pfizer Limited reported revenue of ₹2,519.65 Cr (up 10.45% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹2,519.65 Cr ▲ 10.45%
Profit · FY 2026
₹722.43 Cr ▼ 5.88%
EBITDA · FY 2026
₹1,092.04 Cr ▲ 19.68%
Revenue₹ Cr · Standalone01,0002,0003,000FY 2020: ₹2,152 Cr2,152FY 2020FY 2021: ₹2,239 Cr · +4% YoY2,239+4%FY 2021FY 2022: ₹2,611 Cr · +16.6% YoY2,611+16.6%FY 2022FY 2023: ₹2,425 Cr · -7.1% YoY2,425-7.1%FY 2023FY 2024: ₹2,193 Cr · -9.6% YoY2,193-9.6%FY 2024FY 2025: ₹2,281 Cr · +4% YoY2,281+4%FY 2025FY 2026: ₹2,520 Cr · +10.4% YoY2,520+10.4%FY 2026
Net Profit₹ Cr · Standalone05001,000FY 2020: ₹509 Cr509FY 2020FY 2021: ₹498 Cr · -2.3% YoY498-2.3%FY 2021FY 2022: ₹613 Cr · +23.1% YoY613+23.1%FY 2022FY 2023: ₹624 Cr · +1.9% YoY624+1.9%FY 2023FY 2024: ₹551 Cr · -11.6% YoY551-11.6%FY 2024FY 2025: ₹768 Cr · +39.2% YoY768+39.2%FY 2025FY 2026: ₹722 Cr · -5.9% YoY722-5.9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0250500750Q1'25: ₹563 Cr · +5.9% YoY563+5.9%Q1'25Q2'25: ₹589 Cr · +2.3% YoY589+2.3%Q2'25Q3'25: ₹538 Cr · -0.4% YoY538-0.4%Q3'25Q4'25: ₹592 Cr · +8.3% YoY592+8.3%Q4'25Q1'26: ₹603 Cr · +7.1% YoY603+7.1%Q1'26Q2'26: ₹642 Cr · +9.1% YoY642+9.1%Q2'26Q3'26: ₹645 Cr · +19.9% YoY645+19.9%Q3'26Q4'26: ₹629 Cr · +6.3% YoY629+6.3%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,519.65 Cr ₹2,281.35 Cr ₹2,193.17 Cr ₹2,424.76 Cr ₹2,610.99 Cr ₹2,238.55 Cr ₹2,151.65 Cr
Other Income ₹187.95 Cr ₹172.25 Cr ₹180.51 Cr ₹101.05 Cr ₹62.65 Cr ₹81.12 Cr ₹184.02 Cr
Total Income ₹2,707.6 Cr ₹2,453.6 Cr ₹2,373.68 Cr ₹2,525.81 Cr ₹2,673.64 Cr ₹2,319.67 Cr ₹2,335.67 Cr
Cost of Materials Consumed ₹309.51 Cr ₹272.34 Cr ₹335.8 Cr ₹345.27 Cr ₹354.29 Cr ₹334.74 Cr ₹345.21 Cr
Purchases of Stock-in-Trade ₹608.39 Cr ₹512.75 Cr ₹468.59 Cr ₹471.92 Cr ₹666.64 Cr ₹448.65 Cr ₹483.81 Cr
Changes in Inventories -₹33.59 Cr ₹25.36 Cr -₹11.82 Cr ₹56.48 Cr -₹72.9 Cr ₹14.35 Cr -₹36.62 Cr
Employee Benefit Expense ₹367.97 Cr ₹371.33 Cr ₹347.8 Cr ₹331.68 Cr ₹403.67 Cr ₹361.06 Cr ₹364.51 Cr
Finance Costs ₹9.48 Cr ₹8.41 Cr ₹15.41 Cr ₹13.39 Cr ₹10.49 Cr ₹15.11 Cr ₹10.85 Cr
Depreciation & Amortisation ₹57.73 Cr ₹60.79 Cr ₹62.28 Cr ₹105.51 Cr ₹115 Cr ₹109.41 Cr ₹103.24 Cr
Other Expenses ₹363.28 Cr ₹359.34 Cr ₹417.5 Cr ₹410.55 Cr ₹423.56 Cr ₹367.63 Cr ₹422.18 Cr
Total Expenses ₹1,682.77 Cr ₹1,610.32 Cr ₹1,635.56 Cr ₹1,734.8 Cr ₹1,900.75 Cr ₹1,650.95 Cr ₹1,693.18 Cr
Profit Before Exceptional Items & Tax ₹1,024.83 Cr ₹843.28 Cr ₹738.12 Cr ₹791.01 Cr ₹772.89 Cr ₹668.72 Cr ₹642.49 Cr
Exceptional Items -₹49.16 Cr ₹172.81 Cr ₹7.95 Cr ₹33 Cr ₹0 ₹0 ₹0
Profit Before Tax ₹975.67 Cr ₹1,016.09 Cr ₹746.07 Cr ₹824.01 Cr ₹772.89 Cr ₹668.72 Cr ₹642.49 Cr
Total Tax Expense ₹253.24 Cr ₹248.49 Cr ₹194.74 Cr ₹200.08 Cr ₹160.33 Cr ₹171.11 Cr ₹133.36 Cr
Net Profit ₹722.43 Cr ₹767.6 Cr ₹551.33 Cr ₹623.93 Cr ₹612.56 Cr ₹497.61 Cr ₹509.13 Cr
Other Comprehensive Income ₹3.84 Cr ₹74 Lakh ₹5.45 Cr ₹3.61 Cr ₹7.17 Cr -₹96 Lakh -₹8.93 Cr
Total Comprehensive Income ₹726.27 Cr ₹768.34 Cr ₹556.78 Cr ₹627.54 Cr ₹619.73 Cr ₹496.65 Cr ₹500.2 Cr
EBITDA (computed) ₹1,092.04 Cr ₹912.48 Cr ₹815.81 Cr ₹909.91 Cr ₹898.38 Cr ₹793.24 Cr ₹756.58 Cr
Basic EPS ₹157.92 ₹167.79 ₹120.51 ₹136.38 ₹133.89 ₹108.77 ₹111.28
Diluted EPS ₹157.92 ₹167.79 ₹120.51 ₹136.38 ₹133.89 ₹108.77 ₹111.28
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,921.88 Cr ₹4,911.11 Cr ₹4,228.78 Cr ₹4,000.73 Cr
Non-current Assets ₹1,118.66 Cr ₹1,398.26 Cr ₹1,459.22 Cr ₹1,475.64 Cr
Current Assets ₹3,803.22 Cr ₹3,512.85 Cr ₹2,737.81 Cr ₹2,493.34 Cr
Property, Plant & Equipment ₹136.13 Cr ₹171.82 Cr ₹150.95 Cr ₹177.53 Cr
Inventories ₹472.66 Cr ₹475.92 Cr ₹433.69 Cr ₹417.7 Cr
Trade Receivables ₹181.8 Cr ₹193.09 Cr ₹187.61 Cr ₹151.73 Cr
Cash & Equivalents ₹102.66 Cr ₹495.07 Cr ₹112 Cr ₹36.6 Cr
Equity (Net Worth) ₹4,202.9 Cr ₹4,217.41 Cr ₹3,595.54 Cr ₹3,207.3 Cr
Equity Share Capital ₹45.75 Cr ₹45.75 Cr ₹45.75 Cr ₹45.75 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹2.5 Cr ₹2.5 Cr ₹2.5 Cr ₹2.5 Cr
Total Debt (computed) ₹2.5 Cr ₹2.5 Cr ₹2.5 Cr ₹2.5 Cr
Current Liabilities ₹627.48 Cr ₹569.51 Cr ₹546.56 Cr ₹657.35 Cr
Total Liabilities ₹718.98 Cr ₹693.7 Cr ₹633.24 Cr ₹793.43 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹967.57 Cr ₹659.75 Cr ₹256.84 Cr ₹355.7 Cr ₹667.08 Cr
Investing Cash Flow -₹561.67 Cr -₹71.34 Cr ₹53.7 Cr -₹36.05 Cr -₹575.02 Cr
Financing Cash Flow -₹798.31 Cr -₹205.34 Cr -₹235.14 Cr -₹345.79 Cr -₹180.51 Cr
Capital Expenditure ₹25.23 Cr ₹28.15 Cr ₹18.93 Cr ₹64.98 Cr ₹15.31 Cr
Free Cash Flow (computed) ₹942.34 Cr ₹631.6 Cr ₹237.91 Cr ₹290.72 Cr ₹651.77 Cr
Dividends Paid ₹751.64 Cr ₹160.25 Cr ₹183.43 Cr ₹297.21 Cr ₹159.74 Cr
Net Change in Cash -₹392.41 Cr ₹383.07 Cr ₹75.4 Cr -₹26.14 Cr -₹88.45 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹629.23 Cr ₹645.03 Cr ₹642.34 Cr ₹603.05 Cr ₹591.91 Cr ₹537.99 Cr ₹588.59 Cr ₹562.86 Cr ₹546.63 Cr ₹539.97 Cr ₹575.21 Cr ₹531.36 Cr
Other Income ₹40.72 Cr ₹38.21 Cr ₹41.85 Cr ₹67.17 Cr ₹44.58 Cr ₹42.76 Cr ₹43.07 Cr ₹41.84 Cr ₹75.13 Cr ₹35.85 Cr ₹36.07 Cr ₹33.46 Cr
Total Income ₹669.95 Cr ₹683.24 Cr ₹684.19 Cr ₹670.22 Cr ₹636.49 Cr ₹580.75 Cr ₹631.66 Cr ₹604.7 Cr ₹621.76 Cr ₹575.82 Cr ₹611.28 Cr ₹564.82 Cr
Cost of Materials Consumed ₹83.04 Cr ₹67.78 Cr ₹70 Cr ₹88.69 Cr ₹70.64 Cr ₹67.31 Cr ₹76.65 Cr ₹57.74 Cr ₹88.68 Cr ₹77.23 Cr ₹83.78 Cr ₹86.11 Cr
Purchases of Stock-in-Trade ₹117.69 Cr ₹145.15 Cr ₹221.27 Cr ₹124.28 Cr ₹139.52 Cr ₹104.99 Cr ₹80.65 Cr ₹187.59 Cr ₹93.96 Cr ₹148.6 Cr ₹79.13 Cr ₹146.9 Cr
Changes in Inventories ₹19.63 Cr ₹11.84 Cr -₹63.32 Cr -₹1.74 Cr -₹7.68 Cr ₹24.26 Cr ₹53.42 Cr -₹44.64 Cr ₹6.7 Cr -₹43.27 Cr ₹41.86 Cr -₹17.11 Cr
Employee Benefit Expense ₹77.18 Cr ₹100.3 Cr ₹94.67 Cr ₹95.82 Cr ₹82.91 Cr ₹96.29 Cr ₹100.76 Cr ₹91.37 Cr ₹75.11 Cr ₹89.37 Cr ₹89.8 Cr ₹93.52 Cr
Finance Costs ₹2.11 Cr ₹1.99 Cr ₹2.13 Cr ₹3.25 Cr ₹2.69 Cr ₹1.51 Cr ₹2.1 Cr ₹2.11 Cr ₹6.95 Cr ₹2.86 Cr ₹2.73 Cr ₹2.87 Cr
Depreciation & Amortisation ₹14.78 Cr ₹14.26 Cr ₹14.28 Cr ₹14.41 Cr ₹16.4 Cr ₹14.8 Cr ₹14.99 Cr ₹14.6 Cr ₹13.75 Cr ₹17.55 Cr ₹15.43 Cr ₹15.55 Cr
Other Expenses ₹95.74 Cr ₹91.77 Cr ₹89.79 Cr ₹85.98 Cr ₹79.02 Cr ₹99.15 Cr ₹87.86 Cr ₹93.31 Cr ₹92.75 Cr ₹115.49 Cr ₹98.03 Cr ₹111.23 Cr
Total Expenses ₹410.17 Cr ₹433.09 Cr ₹428.82 Cr ₹410.69 Cr ₹383.5 Cr ₹408.31 Cr ₹416.43 Cr ₹402.08 Cr ₹377.9 Cr ₹407.83 Cr ₹410.76 Cr ₹439.07 Cr
Profit Before Exceptional Items & Tax ₹259.78 Cr ₹250.15 Cr ₹255.37 Cr ₹259.53 Cr ₹252.99 Cr ₹172.44 Cr ₹215.23 Cr ₹202.62 Cr ₹243.86 Cr ₹167.99 Cr ₹200.52 Cr ₹125.75 Cr
Exceptional Items ₹9.04 Cr -₹58.2 Cr ₹0 ₹0 ₹172.81 Cr ₹0 ₹0 ₹0 ₹0 ₹7.95 Cr ₹0 ₹0
Profit Before Tax ₹268.82 Cr ₹191.95 Cr ₹255.37 Cr ₹259.53 Cr ₹425.8 Cr ₹172.44 Cr ₹215.23 Cr ₹202.62 Cr ₹243.86 Cr ₹175.94 Cr ₹200.52 Cr ₹125.75 Cr
Total Tax Expense ₹69 Cr ₹50.11 Cr ₹66.35 Cr ₹67.78 Cr ₹94.86 Cr ₹44.84 Cr ₹56.88 Cr ₹51.91 Cr ₹65 Cr ₹45.96 Cr ₹51.56 Cr ₹32.22 Cr
Net Profit ₹199.82 Cr ₹141.84 Cr ₹189.02 Cr ₹191.75 Cr ₹330.94 Cr ₹127.6 Cr ₹158.35 Cr ₹150.71 Cr ₹178.86 Cr ₹129.98 Cr ₹148.96 Cr ₹93.53 Cr
Other Comprehensive Income ₹3.8 Cr ₹1.87 Cr -₹91 Lakh -₹92 Lakh ₹2.35 Cr -₹54 Lakh -₹53 Lakh -₹54 Lakh ₹7.93 Cr -₹83 Lakh -₹83 Lakh -₹82 Lakh
Total Comprehensive Income ₹203.62 Cr ₹143.71 Cr ₹188.11 Cr ₹190.83 Cr ₹333.29 Cr ₹127.06 Cr ₹157.82 Cr ₹150.17 Cr ₹186.79 Cr ₹129.15 Cr ₹148.13 Cr ₹92.71 Cr
EBITDA (computed) ₹276.67 Cr ₹266.4 Cr ₹271.78 Cr ₹277.19 Cr ₹272.08 Cr ₹188.75 Cr ₹232.32 Cr ₹219.33 Cr ₹264.56 Cr ₹188.4 Cr ₹218.68 Cr ₹144.17 Cr
Basic EPS ₹43.68 ₹31.01 ₹41.32 ₹41.91 ₹72.34 ₹27.89 ₹34.61 ₹32.94 ₹22.33 ₹27.12 ₹32.56 ₹20.44
Diluted EPS ₹43.68 ₹31.01 ₹0.00 ₹41.91 ₹72.34 ₹27.89 ₹0.00 ₹32.94 ₹22.33 ₹27.12 ₹32.56 ₹20.44
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Pfizer Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Pfizer Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 63.92%, foreign institutional investors hold 2.81%, domestic institutional investors hold 16.89%, retail and other public shareholders hold 16.37% of Pfizer Limited. The company had 99,545 shareholders on record.

Promoters: 63.92%DII (Domestic Institutional): 16.89%FII (Foreign Institutional): 2.81%Retail & Others: 16.37%
Mar 2026
QUARTER
63.92% Promoters
16.89% DII (Domestic Institutional)
2.81% FII (Foreign Institutional)
16.37% Retail & Others
Promoter holding - history
Now 63.92% · Mar 2026High 63.92% · Dec 2015Low 63.92% · Dec 2015
62%62.8%63.5%64.3%65%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 63.92%Mar 2016: 63.92%Jun 2016: 63.92%Sep 2016: 63.92%Dec 2016: 63.92%Mar 2017: 63.92%Jun 2017: 63.92%Sep 2017: 63.92%Dec 2017: 63.92%Mar 2018: 63.92%Jun 2018: 63.92%Sep 2018: 63.92%Dec 2018: 63.92%Mar 2019: 63.92%Jun 2019: 63.92%Sep 2019: 63.92%Dec 2019: 63.92%Mar 2020: 63.92%Jun 2020: 63.92%Sep 2020: 63.92%Dec 2020: 63.92%Mar 2021: 63.92%Jun 2021: 63.92%Sep 2021: 63.92%Dec 2021: 63.92%Mar 2022: 63.92%Jun 2022: 63.92%Sep 2022: 63.92%Dec 2022: 63.92%Mar 2023: 63.92%Jun 2023: 63.92%Sep 2023: 63.92%Dec 2023: 63.92%Mar 2024: 63.92%Jun 2024: 63.92%Sep 2024: 63.92%Dec 2024: 63.92%Mar 2025: 63.92%Jun 2025: 63.92%Sep 2025: 63.92%Dec 2025: 63.92%Mar 2026: 63.92%63.92%63.92%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters63.92%63.92%63.92%63.92%63.92%63.92%
Public36.08%36.08%36.08%36.08%36.08%36.08%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
Public36.08%36.08%36.08%36.08%36.08%36.08%36.08%36.08%36.08%36.08%36.08%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Pfizer Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Pfizer Limited has 7 directors - 3 independent and 3 executive. The board is chaired by Pradip Shah.

DirectorPositionOn board sinceListed boards
Pradip Shah Non-Executive - Non Independent Director · Chairperson 2024-11-10 4
Meena Ganesh Non-Executive - Independent Director 2019-03-08 5
Lakshmanan Krishnakumar Non-Executive - Independent Director 2024-07-29 1
Sonia Singh Non-Executive - Independent Director 2024-07-29 5
Meenakshi Nevatia Executive Director · CEO-MD 2023-04-03 2
Amit Agarwal Executive Director 2024-02-26 1
P Rengan Executive Director 2023-10-28 1
Board Committees
CommitteeMembers
Audit Committee Lakshmanan Krishnakumar (Chairperson), Pradip Shah, Meena Ganesh
Nomination and remuneration committee Meena Ganesh (Chairperson), Pradip Shah, Lakshmanan Krishnakumar, Sonia Singh
Stakeholders Relationship Committee Meena Ganesh (Chairperson), Lakshmanan Krishnakumar, Meenakshi Nevatia, P Rengan
Risk Management Committee Sonia Singh (Chairperson), Meena Ganesh, Meenakshi Nevatia, Amit Agarwal
Corporate Social Responsibility Committee Pradip Shah (Chairperson), Sonia Singh, Meenakshi Nevatia, Amit Agarwal, P Rengan
Board Administrative and Share Transfer Committee Meenakshi Nevatia (Chairperson), Amit Agarwal, P Rengan

Charges & Borrowings Pfizer Limited

Pfizer Limited does not have any charges (loans) registered with the Registrar of Companies.

Employees and EPFO Compliance at Pfizer Limited

Pfizer Limited has a workforce of 1,727 employees as of Mar 21, 2024.

Employee count
1,727
Active EPFO establishments
3
Employee growth
-6.65%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Pfizer Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Pfizer Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Pfizer Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Pfizer Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Pfizer Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Pfizer Limited

MSME Payment Delays by Pfizer Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Pfizer Limited

Subsidiaries & Group Companies of Pfizer Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Pfizer Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Pfizer Limited

MCA Filings & Documents of Pfizer Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Pfizer Limited

Activity
21 Jul 2025
Pfizer Limited last Annual general meeting of members was held on 21 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Pfizer Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Directors
29 Jul 2024
Sonia Singh was appointed as a Director on 29 Jul 2024 & has been associated with this company since 1 year 11 months.
Directors
29 Jul 2024
Lakshmanan Krishna Kumar was appointed as a Director on 29 Jul 2024 & has been associated with this company since 1 year 11 months.
Directors
07 Mar 2024
Amit Agarwal was appointed as a Cfo on 07 Mar 2024 & has been associated with this company since 2 years 4 months.
Directors
26 Feb 2024
Amit Agarwal was appointed as a CFO on 26 Feb 2024 & has been associated with this company since 2 years 4 months.

Recent News on Pfizer Limited

Frequently Asked Questions about Pfizer Limited

Pfizer Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 21 November 1950 (76+ years old) and is registered under CIN L24231MH1950PLC008311. Listed on BSE: 500680 and NSE: PFIZER. The company has 1,727 employees.

Pfizer Limited reported revenue of ₹2,453.6 Cr for FY 2025 (up 3.00% YoY).

The current directors of Pfizer Limited are:

The primary industry of Pfizer Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Pfizer Limited is listed on both BSE (code: 500680) and NSE (symbol: PFIZER).

Pfizer Limited can be reached at the registered office: The Capital 1802 1901 Plot No. C – 70 G Block Bandra Kurla Complex Bandra East, Mumbai, Maharashtra, India – 400051, or through the website pfizerindia.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available